InspireMD Completes First U.S. Commercial Transcarotid Artery Revascularization Procedures Utilizing Its CGuard Prime TransCarotid Stent System

Benzinga · 1d ago

- First commercial cases mark return of the CGuard Prime platform to the U.S. market -

- Milestone expands commercial application of proprietary MicroNet™ Mesh-covered CGuard Prime stent platform to include transcarotid artery revascularization ("TCAR") procedures –

MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime Carotid Stent for the prevention of stroke, today announced the successful completion of the first U.S. commercial transcarotid artery revascularization ("TCAR") procedures utilizing its CGuard® Prime TransCarotid Stent System, following U.S. Food and Drug Administration ("FDA") pre-market approval ("PMA") of the device on November 9, 2026. Among the first physicians to perform commercial cases with the system were Brett Almond, M.D., at Bay Surgical Specialists, greater Tampa Bay area, Florida; Gregory T. Clabeaux, D.O., at Sisters of Charity Hospital, part of Catholic Health, in Buffalo, New York; and Bradley R. Grimsley, M.D., at Baylor Scott & White in Dallas, Texas.

The first commercial cases mark an important step in the U.S. rollout of the CGuard® Prime TransCarotid Stent System, a delivery system designed for transcarotid access. The system enables physicians to use InspireMD’s proprietary MicroNet™ mesh-covered stent technology during TCAR procedures with a compatible FDA-cleared neuroprotection system.